Table 2.

Legend critical appraisal. Assessment per item for critical appraisal of selected studies.

Directness of Evidence (DoE)
Study design	CT, clinical trial PCS, prospective case series RCS, retrospective case series RCT, randomized control trial
Indication for treatment Diagnosis	Clearly reported, ● Not clearly reported, ○
Demographic data Age at treatment	Individually reported, ● Means reported, ◑ Not reported, ○
Treatment approach NF used, dosage, route of administration	Reported, ● Not reported, ○
Efficacy outcome measures Pre and post treatment assessment	Reported, ● Not reported, ○
Safety assessment Quantifiable adverse events per patient If drug was attributed to reported adverse events	Reported per patient or per event, ● Events reported but not quantified, ◑ Not reported, ○
Follow-up Duration of follow-up at the end of treatment for all tested individuals	˃2 months, ● <2 months, ◑ not reported, ○
Overall DoE score	High, ≥5 points Moderate, between 4–5 points Low, <4
Risk of Bias (RoB)
Randomization	Randomized or concealed, ● Not randomized or concealed, ○
Blinding	Blinding of patient, researcher, observer, ● Single blind, ◑ No blinding, ○
Standardization of treatment	All patients received the same therapy, ● Different types of NFs or dosage used, ◑ Dosage modified throughout trial, ○
Standardization of outcome measures	Identical outcome reports, ● Reported however not standardized, ◑ Not reported, ○
Standardization of follow up	Identical follow up for all patients, ● Reported however not standardized, ◑ Not reported, ○
Missing data	No missing data; missing data mentioned/quantified and Method of handling described, ● Missing data mentioned in study but method of handling Not described, ◑ Missing data not reported, ○
Overall RoB score	Low, ≥5 points Moderate, between 4–5 points High, <4

Grading (● = 1 Point, ◑ = 0.5 Point, ○ = 0 Point).